Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The DENOCHARCOT Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04547348
Recruitment Status : Not yet recruiting
First Posted : September 14, 2020
Last Update Posted : September 14, 2020
Sponsor:
Information provided by (Responsible Party):
Ole Lander Svendsen, Bispebjerg Hospital

Brief Summary:
The aim of the present trial is to assess the efficacy of treatment of acute Charcot foot in diabetes patients with Prolia® on clinical relevant Outcomes in a randomized, double blind, placebo-controlled trial.

Condition or disease Intervention/treatment Phase
Charcot Foot Diabetes Mellitus Drug: Denosumab Injection Phase 3

Detailed Description:

After giving informed consent and being enrolled, patients will be randomized to one of two group given either Denosumab treatment or injection with placebo. The patients will then undergo a 52 week follow up with regular controls to asses if clinical signs of Charcot is in remission, which will be verified using relevant radiological modalities. Upon final visit the patients will be examined using radiology, blood samples, biothesiometry and objective examinations, following up on the same examinations being made upon inclusion.

Primary outcome will be time until full remission of the Charcot foot defined as clinical healing (The acute Charcot foot is clinically healed when the temperature difference at the site maximum temperature on the affected Charcot foot is < 2 degrees Celsius compared to the similar site on the contra-lateral foot, measured using an infrared thermometer, and edema and redness of the skin has subsided) followed up by radiological signs of healing.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 38 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Efficacy of Treatment With DENOsumab of an Acute CHARCOT Foot in Patients With Diabetes. A Multicenter, Double-blind, Randomized, Placebo-controlled Trial.
Estimated Study Start Date : September 1, 2020
Estimated Primary Completion Date : October 1, 2023
Estimated Study Completion Date : October 1, 2026

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Foot Health
Drug Information available for: Denosumab

Arm Intervention/treatment
Experimental: Denosumab treated group
Participants will receive a 60 mg subcutaneous injection of Prolia upon randomization and on week 28 after the first injection provided remission of the Charcot foot has not been achieved by then
Drug: Denosumab Injection
Injections made subcutaneously per standard description

Placebo Comparator: Placebo treated group
Participants will receive an injection of placebo produced by the same provider as the prolia drug of equivalent volume at the same time points as the treated group
Drug: Denosumab Injection
Injections made subcutaneously per standard description




Primary Outcome Measures :
  1. Time until remission [ Time Frame: 52 weeks ]
    Time from first injection of IP until the time point where the acute Charcot foot is clinically healed/in remission, ie. the temperature difference at the site maximum temperature on the affected Charcot foot is < 2 degrees Celsius compared to the similar site on the contra-lateral foot, measured using an infrared thermometer, and edema and redness of the skin has subsided - at two subsequent visits 4 weeks apart. The off-loading regime will be continued until the second visit. The first of the two visits is the timepoint of healing of the acute Charcot foot.


Secondary Outcome Measures :
  1. Fraction of clinical healed participants at each study visit. [ Time Frame: 52 weeks ]
  2. Fraction of healing on X-rays and MRI (or PET/CT or Scintigram) at the time of clinical healing and at the End of trial. [ Time Frame: 52 weeks ]
  3. Number of relapses (defined as need for/prescription of off- loading with cast of the Charcot foot again) [ Time Frame: 52 weeks ]
  4. Time without relapse (the time from clinical healing/remission to the relapse or to End of Trial at 12 months). [ Time Frame: 52 weeks ]
  5. Number of patients with development of complications to the acute Charcot foot, as well as number of development of foot ulcer, deformity, need for special footwear or surgery and fractures of bones in the foot, respectively. [ Time Frame: 52 weeks ]
  6. Changes in BMD (lumbar spine, hip) [ Time Frame: 52 weeks ]
  7. Changes in markers of bone turnover (CTX and P1NP) [ Time Frame: 52 weeks ]
  8. Changes in markers of glycemic control (HbA1c) [ Time Frame: 52 weeks ]
  9. Incidence of Adverse Events and Serious Adverse Events [ Time Frame: 52 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 18-80 years
  • Type 1 or type 2 diabetes (diagnosed diabetes for more than 3 months)
  • Diagnosed with acute Charcot foot defined as a unilateral red, swollen and warm foot, with a difference of skin temperature of more than 2 °C compared with the unaffected foot and with sign of Charcot on either x-rays of the foot, MRI, bone scintigram or PET/CT.
  • Peripheral neuropathy: Previously diagnosed and/or biothesiometri: > 25 V or lack of sensation of 10 grams monofilament on 1. toe at the acute Charcot foot.

Exclusion Criteria:

  • Duration of the acute Charcot foot for more than 3 months (at the screening visit).
  • Existing foot ulcer on the affected foot
  • Previous acute or chronic Charcot of the affected foot
  • Planned surgery on the acute Charcot foot
  • Infection (cellulitis or osteomyelitis) of the affected foot (clinically and/or radiologically proven)
  • Previous midfoot or proximal to mid foot amputation of the affected foot
  • Hypocalcemia (Serum Calcium <2.1 mmol/L or Calcium ion < 1.12 mmol/L)
  • Vitamin D deficiency (Serum 25-hydroxyvitamin D < 50 nmol/L)
  • Renal failure (serum creatinine >200 mmol/L or eGFR < 30 ml/min).
  • Treatment with Denosumab within the last 12 months. • Have a known hypersensitivity to Denosumab • History of osteonecrosis of the jaw.
  • Poor oral hygiene, which is defined as within 3 months of a tooth extraction, dental implants or mandibular surgery
  • Planned mandibular surgery or dental implants within the next 12 months.
  • Prior non-traumatic vertebral fracture
  • Treatment with medication known to affect bones within the last 12 months (such as bisphosphonates, Forsteo®, calcitonin, Protelos®, selective estrogen receptor modulators, glucocorticoids and sex hormones)
  • Active or chronic liver disease *Chronic liver disease is defined as clinical history of decompensated chronic liver disease (ascites, encephalopathy or variceal bleeding) *Acute Liver disease is defined as an INR of > 1.5 (in the absence of the use of Warfarin) and AST and ALT > 2 x ULN
  • History of inflammatory arthropathies (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, autoimmune arthropathy)
  • Pre-existing medical condition judged to preclude safe participation in the study
  • Current treatment with cytotoxic drugs or with systemically administered glucocorticoids
  • Abuse of alcohol or drugs, or presence of any condition that in the Investigators opinion may lead to poor adherence to study protocol
  • Pregnancy, breast feeding or planning pregnancy or not using adequate contraceptive methods. The following contraceptive products are considered to be safe: Intrauterine devices or hormonal contraception (oral contraceptive pills, implants, transdermal patches, vaginal rings or long-acting injections).
  • Likely inability to comply with the visits because of planned activity
  • Use of any investigational product with the last month.
  • Use of any drug or any other reason which in the Investigator's opinion could interfere with the outcome of the treatment of the acute Charcot foot.
  • Cancer, or any clinically significant disease or disorder, except for conditions associated to the diabetes, which in the Investigator's opinion could interfere with the results of the trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04547348


Contacts
Layout table for location contacts
Contact: Ole Lander Svendsen, MD +4521490547 Ole.Lander.Svendsen@regionh.dk
Contact: Michael Zaucha Sørensen, MD +4526836584 mzs@dadlnet.dk

Sponsors and Collaborators
Ole Lander Svendsen
Investigators
Layout table for investigator information
Study Chair: Ole Lander Svendsen, MD Region Hovedstaden
Additional Information:
Publications:

Layout table for additonal information
Responsible Party: Ole Lander Svendsen, Professor, Bispebjerg Hospital
ClinicalTrials.gov Identifier: NCT04547348    
Other Study ID Numbers: CODIF-008
First Posted: September 14, 2020    Key Record Dates
Last Update Posted: September 14, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Denosumab
Bone Density Conservation Agents
Physiological Effects of Drugs